The Pointy End of the TGA (PI) Reformatting Transition Period

TGA's new Product Information (PI) Form: If you need support to meet the 31 December 2020 deadline, we’re here to help.

By now, we should all be very familiar with the new Form for providing  TGA Product Information (PI) for Australia Each time you make a change to a PI, be it safety-related or otherwise, you’re required to provide the updated PI to TGA in the new format.

The looming deadline for marketed product PIs to be in the new format is  31 December 2020 . As we are already in mid-March, that’s not very far away. However, more than two thirds of the way through the transition period, a review of a random sample of PIs indicates that approximately  45% of products on the ARTG are still in the old format!

TGA are trying to help Sponsors meet the deadline. To encourage submissions, they have introduced a fee exemption, until the end of the year, for applications where the only change is to reformat the PI and no other editorial changes are made.

What can you do to make the process easier?

  1. Establishing a robust template is extremely important. Although the TGA have provided a bookmarked template, it can be significantly upgraded to include mandatory and standard TGA statements, as well as standardised company preferred text and instructions for the reformatting party.
  2. Documenting PI reformatting decisions and implementing them consistently across the organisation is also key to improving efficiency. Reformatting is not an exact science – variability abounds.

If you need support to meet the 31 December 2020 deadline, we’re here to help.

Our team of regulatory experts and medical writers can efficiently manage your PI reformatting as an outsourced project, relieving the burden on you and your team. Take the stress out of your PI reformatting project today by contacting us.

Contact us today for an initial consultation and learn how we can add value to your business.

More recent articles

  • Pharmaceutical Quality Assurance Australia and NZ

    Pharmaceutical Quality Assurance Australia and NZ

    The Critical Importance of Quality Assurance (QA) in Drug Development, Clinical Trials, and Importation into Australia and New Zealand. Why Pharmaceutical Quality Assurance Matters Maintaining high-quality standards throughout every stage of drug development, including nonclinical research, clinical trials, manufacturing, supply chain, and importation, is essential for protecting patient safety, ensuring product efficacy, and fulfilling regulatory…

  • Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    Australia and the ACCESS Consortium: Navigating Regulatory Collaboration

    The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…

  • Life Sciences Expansion Strategies Greater Bay Area – China

    Life Sciences Expansion Strategies Greater Bay Area – China

    China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…